ReviewFrontiers in pharmacology2026
A narrative review of stem cell-based therapy for fibrosing interstitial lung diseases: clinical evidence and translational perspectives.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrosing interstitial lung diseases (F-ILD) are a heterogeneous group of disorders characterized by pulmonary interstitial fibrosis and inflammation. Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of F-ILD. Regulator-approved anti-fibrotic drugs, such as pirfenidone and nintedanib, delay rather than reverse disease progression, so the threat of eventual respiratory failure remains. While lung transplantation is an option that can prolong survival for end-stage IPF, its clinical application is greatly restricted by donor shortages, surgical risks, and postoperative complications. Stem cell therapies, and particularly treatments based on mesenchymal stromal/stem cells (MSCs) and their derivatives, have brought new hope for the management of F-ILD due to their immune regulatory, anti-inflammatory, and anti-fibrotic capabilities. A search was conducted to identify relevant articles in the PubMed/MEDLINE, Web of Science, Cochrane Library, China National Knowledge Internet and Wanfang Data from inception to 31st May 2026. This review summarizes the mechanistic overview of stem cell-based therapeutic strategies for F-ILD, safety profiles and therapeutic potentials of various stem cells for the treatment of IPF and other F-ILDs, with an emphasis on stem cell types and delivery routine. This article also discusses the challenges and limitations of stem cell-based therapies, highlighting the need for further clinical studies with standardized efficacy endpoints to validate their effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.